You are here

Article info

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma

Authors

  • Pei-Chang Lee Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Yee Chao Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Ming-Huang Chen Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Keng-Hsin Lan Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • I-Cheng Lee Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Ming-Chih Hou Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Yi-Hsiang Huang Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Yi-Hsiang Huang; yhhuang{at}vghtpe.gov.tw
View Full Text

Citation

Lee P, Chao Y, Chen M, et al
Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer 2020;8:e001072. doi: 10.1136/jitc-2020-001072

Publication history

  • Accepted August 1, 2020
  • First published August 30, 2020.
Online issue publication 
August 30, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.